A class of drugs originally developed for type 2 diabetes now reduces the risk of kidney failure by roughly 30 to 40 percent in patients with chronic kidney disease, according to data from major clinical trials published in the New England Journal of Medicine. SGLT2 inhibitors — sometimes called “flozins” — have emerged as the most significant advancement in kidney disease treatment in decades, with dapagliflozin (Farxiga) cutting the risk of serious kidney decline by 39 percent and empagliflozin (Jardiance) reducing progression by 28 percent. For the estimated 37 million Americans living with chronic kidney disease, roughly one in seven adults, these findings represent a genuine shift in what was previously a slow march toward dialysis or transplant for many patients.
What makes this especially relevant for those concerned with brain health and dementia care is the well-documented connection between kidney function and cognitive decline. Chronic kidney disease accelerates vascular damage throughout the body, including the brain, and patients with advanced CKD face significantly higher rates of dementia and cognitive impairment. A treatment that preserves kidney function may therefore carry protective benefits well beyond the kidneys themselves. This article examines the clinical evidence behind these drugs, how they compare to one another, who benefits most, and what newer treatments on the horizon might mean for patients managing both kidney disease and long-term brain health.
Table of Contents
- Which Chronic Kidney Disease Drugs Cut Kidney Failure Risk by 30 Percent or More?
- How SGLT2 Inhibitors Work and Where They Fall Short
- The Kidney-Brain Connection and Why Kidney Protection Matters for Dementia Risk
- Comparing SGLT2 Inhibitors to Newer CKD Treatments
- Risks and Realities of Managing CKD Medications in Dementia Patients
- What Caregivers Should Ask the Nephrologist
- Where CKD Treatment Is Headed
- Conclusion
- Frequently Asked Questions
Which Chronic Kidney Disease Drugs Cut Kidney Failure Risk by 30 Percent or More?
The drugs responsible for the headline-grabbing 30 percent reduction belong to the SGLT2 inhibitor class, and two have the strongest clinical backing. Dapagliflozin, sold as Farxiga, was tested in the landmark DAPA-CKD trial, where it produced a 39 percent reduction in the primary composite outcome of sustained kidney function decline, end-stage kidney disease, or death from renal or cardiovascular causes. Breaking that down further, the trial showed a 36 percent reduction in end-stage kidney disease specifically and a 47 percent reduction in sustained 50 percent eGFR decline. The number needed to treat was 19, meaning that for every 19 patients given the drug, one avoided a major kidney event — a strong result by any clinical standard. Empagliflozin, marketed as Jardiance, showed a 28 percent reduction in the risk of kidney disease progression or cardiovascular death in the EMPA-KIDNEY trial, also published in the new England Journal of Medicine in 2022.
While the reduction was slightly more modest than dapagliflozin’s, both drugs demonstrated benefits in patients with and without diabetes, which was a critical finding. Previously, CKD treatment options were largely limited to blood pressure control and diabetes management. These trials established SGLT2 inhibitors as a foundational therapy for chronic kidney disease itself, regardless of diabetic status. The 2024 KDIGO guidelines and the 2026 American Diabetes Association Standards of Care now recommend SGLT2 inhibitors as foundational therapy for CKD management across all kidney function levels. This is not a fringe recommendation — it reflects consensus among the major professional bodies that guide kidney care worldwide.
How SGLT2 Inhibitors Work and Where They Fall Short
SGLT2 inhibitors work by blocking a protein in the kidneys that reabsorbs glucose back into the bloodstream. By preventing this reabsorption, the drugs reduce pressure inside the kidney’s filtering units, called glomeruli, which slows the progressive scarring that drives CKD toward kidney failure. They also promote modest glucose and sodium excretion, which produces secondary benefits for blood sugar control, blood pressure, and fluid balance. The mechanism is elegant in its simplicity — rather than adding a new chemical signal to the body, these drugs essentially reduce the workload on already-damaged kidneys. However, SGLT2 inhibitors are not without limitations. They carry a known risk of genital yeast infections and urinary tract infections due to increased glucose in the urine.
In some patients, particularly those who are volume-depleted or on multiple blood pressure medications, they can cause episodes of low blood pressure or dehydration. There have also been rare reports of diabetic ketoacidosis, even in patients with normal blood sugar levels, which means anyone starting these medications needs clear guidance on warning signs. For frail elderly patients, especially those already managing dementia-related challenges with hydration and nutrition, these side effects require careful monitoring. If a patient has very advanced kidney disease with an eGFR below 20, the clinical benefit becomes less certain, and the drug’s glucose-lowering effect diminishes substantially. Physicians must weigh whether starting the medication at that stage still offers meaningful kidney protection or primarily introduces risk. This is a conversation worth having with a nephrologist rather than assuming the drug is universally beneficial at every stage of disease.
The Kidney-Brain Connection and Why Kidney Protection Matters for Dementia Risk
The link between chronic kidney disease and cognitive decline is not speculative — it is one of the more consistent findings in vascular neurology research. CKD promotes systemic inflammation, accelerates atherosclerosis, and disrupts the regulation of uremic toxins that accumulate in the blood when kidneys falter. These toxins cross the blood-brain barrier and contribute to the kind of small vessel damage that underlies vascular dementia, the second most common form of dementia after Alzheimer’s disease. Consider a 68-year-old patient with stage 3 CKD and mild cognitive impairment. Their nephrologist starts dapagliflozin to slow kidney decline, which stabilizes their eGFR over the following two years.
During that same period, the reduced vascular stress may also slow the accumulation of white matter lesions in the brain — the silent markers of small vessel disease that neurologists see on MRI scans. While no trial has yet proven that SGLT2 inhibitors directly prevent dementia, the biological plausibility is strong, and several observational studies have begun to suggest a correlation between preserved kidney function and slower cognitive decline. For families managing a loved one’s care across multiple specialists, this connection is worth raising explicitly. A cardiologist may prescribe these drugs for heart failure, a nephrologist for kidney protection, and neither may discuss the potential cognitive implications. Coordinating that conversation is especially important for patients already showing signs of memory problems.
Comparing SGLT2 Inhibitors to Newer CKD Treatments
SGLT2 inhibitors are no longer the only promising drug class for chronic kidney disease. Semaglutide, the GLP-1 receptor agonist better known by its brand names Ozempic and Wegovy, received FDA approval in January 2025 as an injectable treatment for CKD in patients with type 2 diabetes. Clinical trials showed a 24 percent lower risk of major kidney events, and the drug also reduces the risk of death from kidney or cardiovascular disease. For patients who are already taking semaglutide for weight management or blood sugar control, this added kidney benefit may simplify their medication regimen. Finerenone, sold as Kerendia, takes yet another approach. This mineralocorticoid receptor antagonist showed a 25 percent reduction in the urine albumin-to-creatinine ratio compared to placebo over six months in the FINE-ONE trial, with results announced in November 2025.
Notably, this trial focused on patients with type 1 diabetes and CKD, a population that has historically had fewer targeted treatment options. Finerenone works by blocking inflammatory and fibrotic pathways in the kidney, complementing rather than duplicating the mechanism of SGLT2 inhibitors. The tradeoff between these options is real. SGLT2 inhibitors have the broadest evidence base and work in both diabetic and non-diabetic CKD. Semaglutide requires injections and is currently approved only for CKD patients with type 2 diabetes. Finerenone adds kidney protection but requires monitoring for elevated potassium levels, a particular concern in patients with already-compromised kidney function. For many patients, the future of CKD management will likely involve combinations of these drugs, though the optimal pairings are still being studied.
Risks and Realities of Managing CKD Medications in Dementia Patients
Managing chronic kidney disease medications in someone with cognitive impairment introduces challenges that clinical trials rarely address. SGLT2 inhibitors require adequate hydration to be used safely, but patients with moderate to advanced dementia may not recognize thirst, may refuse fluids, or may be unable to communicate symptoms of dehydration or urinary tract infection. Caregivers become the front line of medication safety in these situations, and they need clear, practical guidance — not just a pharmacy printout. There is also the question of polypharmacy.
A patient with CKD, hypertension, diabetes, and early-stage dementia might be taking eight or more medications. Adding an SGLT2 inhibitor is clinically justified based on the evidence, but every additional pill increases the risk of drug interactions, dosing errors, and caregiver burden. Deprescribing — the deliberate reduction of unnecessary medications — should be part of any conversation about adding new treatments in this population. One warning that often goes unspoken: if a patient with dementia is transitioned to hospice or comfort-focused care, continuing aggressive CKD treatment may no longer align with their goals. Families should discuss with their care team at what point kidney-protective medications shift from beneficial to burdensome, and these conversations are best had early, before a crisis forces the decision.
What Caregivers Should Ask the Nephrologist
When accompanying a loved one with cognitive concerns to a nephrology appointment, caregivers should bring specific questions rather than relying on the physician to volunteer information about the kidney-brain connection. Useful questions include whether the patient’s current kidney function trajectory increases their dementia risk, whether an SGLT2 inhibitor is appropriate given their cognitive and functional status, and what hydration targets should be maintained at home. Asking about lab monitoring frequency is also practical — SGLT2 inhibitors typically require kidney function and electrolyte checks within weeks of starting, and someone needs to ensure those appointments happen.
A real-world example: a caregiver in a support group recently described learning that her mother’s worsening confusion coincided with a drop in kidney function that had gone unmonitored for six months after a medication change. The confusion was not Alzheimer’s progression — it was partially reversible uremic encephalopathy. That scenario underscores why kidney health should be on every dementia caregiver’s radar.
Where CKD Treatment Is Headed
The next several years will likely bring clearer answers about combination therapy — specifically, whether pairing SGLT2 inhibitors with GLP-1 receptor agonists or finerenone produces additive kidney protection or introduces unacceptable risk. Early signals from ongoing trials are encouraging, and the National Kidney Foundation has described these medication classes as “game-changing” for kidney disease management. The broader shift in nephrology is toward earlier, more aggressive intervention rather than waiting until kidney function has deteriorated to the point of near-failure.
For the dementia care community, the more intriguing frontier is whether kidney-protective drugs might eventually be studied specifically for their cognitive benefits. The vascular pathways are well understood, the drug safety profiles are increasingly established, and the patient population — older adults with multiple comorbidities — overlaps almost entirely. Until those trials happen, preserving kidney function remains one of the most actionable steps a person can take to protect not just their kidneys, but quite possibly their brain.
Conclusion
SGLT2 inhibitors have fundamentally changed the outlook for chronic kidney disease, delivering a 28 to 39 percent reduction in kidney failure risk across landmark trials. Combined with newer options like semaglutide and finerenone, patients now have multiple evidence-based tools to slow disease progression — a situation that did not exist a decade ago. For the roughly 37 million Americans with CKD, the question is no longer whether effective treatments exist, but whether patients and their physicians are using them early enough.
For those navigating the intersection of kidney disease and cognitive health, the message is straightforward: kidney protection is brain protection. Ensuring that CKD is actively managed, that appropriate medications are started when indicated, and that caregivers are equipped to monitor for side effects can make a meaningful difference in both kidney outcomes and long-term cognitive trajectory. These are conversations worth having now, not after the next alarming lab result.
Frequently Asked Questions
Do SGLT2 inhibitors work for kidney disease even if a patient does not have diabetes?
Yes. Both the DAPA-CKD and EMPA-KIDNEY trials demonstrated significant kidney protection in patients with and without diabetes. This was one of the most important findings from these studies, and current guidelines recommend SGLT2 inhibitors for CKD regardless of diabetic status.
Can SGLT2 inhibitors and semaglutide be taken together for kidney disease?
Some patients may benefit from both, but this combination has not been extensively studied in dedicated trials for CKD specifically. The decision to combine these medications should be made with a nephrologist who can assess individual risk factors, kidney function, and potential drug interactions.
How quickly do SGLT2 inhibitors show kidney benefits?
In clinical trials, separation between the treatment and placebo groups became apparent within months, and the DAPA-CKD trial was actually stopped early because the benefit was so clear. However, individual patients may not notice symptomatic changes since kidney protection is largely measured through lab values like eGFR and albumin-to-creatinine ratio.
Does chronic kidney disease directly cause dementia?
CKD does not cause dementia in the way that Alzheimer’s pathology does, but it significantly increases the risk of cognitive impairment through vascular damage, inflammation, and the accumulation of uremic toxins. Patients with advanced CKD have markedly higher rates of both vascular dementia and overall cognitive decline compared to age-matched individuals with normal kidney function.
Are these kidney drugs safe for elderly patients with memory problems?
They can be, but with caveats. Adequate hydration must be maintained, and someone — whether the patient or a caregiver — needs to reliably manage the medication schedule and attend follow-up lab appointments. The benefits of kidney protection are substantial, but the practical demands of the medication must be realistic for the patient’s living situation.
What is the number needed to treat for dapagliflozin in CKD?
In the DAPA-CKD trial, the number needed to treat was 19, meaning that treating 19 patients with dapagliflozin for the trial duration prevented one major kidney event. This is considered a strong result in nephrology, where previous interventions often required treating many more patients to achieve measurable benefit.
